Normal Human Immunoglobulin (CSL Behring)(Normal Human Immunoglobulin (CSL Behring)) - 在研适应症：继发性免疫缺陷，获得性免疫缺陷综合征，丙种球蛋白缺乏血症_专利_临床

概要

基本信息

药物类型

免疫球蛋白

别名

Freeze-dried pH4 treatedhuman immunoglobulin、IgG、Immune Globulin Intravenous (Human) (CSL Behring)

+ [22]

靶点-

作用机制-

治疗领域

免疫系统疾病感染神经系统疾病+ [6]

在研适应症

继发性免疫缺陷获得性免疫缺陷综合征丙种球蛋白缺乏血症+ [7]

非在研适应症

非布鲁顿型无丙种球蛋白血症Bruton型无丙种球蛋白血症普通可变性免疫缺陷+ [5]

原研机构

CSL Behring LLC

在研机构

CSL Behring AGCSL Behring GmbH

CSL Behring LLC

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2000-07-27),

原发性免疫缺陷疾病免疫性血小板减少症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

67

项与 Normal Human Immunoglobulin (CSL Behring) 相关的临床试验

NCT06524739

/ Recruiting临床3期

Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immunoglobulin, HIZENTRA®) in Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 [COVID-19] POTS [post-COVID-POTS]).

开始日期2024-08-28

申办/合作机构

CSL Behring LLC

NCT05193552

/ Recruiting临床4期IIT

A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients With Potentially Reversible Airway Disease

Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists regarding the use of spirometry in titrating IG therapy to assist in the management of immunodeficiency patients with regards to gammaglobulin replacement therapy.
The investigators propose to study the use of spirometry to identify patients that could potentially benefit from an increase in IGRT. The investigators will identify 22 common variable immune deficiency (CVID) study subjects on stable IGRT replacement therapy equivalent to 0.40 to 0.60 gm/kg per 4 weeks who have evidence of mild to moderate obstruction as assessed by an FEF25-75% between 50% and 80% of predicted. Patients who are on Hizentra will be preferentially recruited. Of these 22, 11 will be identified at random and treated for 6 months at their current dose (control population). The remaining 11 study subjects (treatment group) will have their level of IGRT increased by the equivalent of 0.05 gm/kg in dose per 4 weeks, adjusted for bioavailability as per manufacturer's instructions. On average, rounded up to the nearest gram, this will typically increase their dose of Hizentra by 2 gm per week.

开始日期2024-01-15

申办/合作机构

The University of Alabama at Birmingham

NCT05614128

/ RecruitingN/AIIT

Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP

The goal of this observational study is to learn about chronic inflammatory demyelinating polyneuropathy. The main question the investigators would like to answer is 1) can skin biopsy identify demyelination better than nerve conduction studies (electrical tests of the nerves)? and 2) how do nerves improve after treatment in CIDP? Participants will be asked to undergo skin biopsy of the finger at baseline and at 3 months and 6 months after treatment with IVIG (which is the FDA approved treatment for CIDP).

开始日期2023-02-28

申办/合作机构

Vanderbilt University Medical Center

[+1]

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的临床结果

登录后查看更多信息

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的转化医学

登录后查看更多信息

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的专利（医药）

登录后查看更多信息

691

项与 Normal Human Immunoglobulin (CSL Behring) 相关的文献（医药）

2025-01-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The interaction of cinchonine and immunoglobulin G and the development of a nanocomplex with improved anti-breast cancer activity

Article

作者: Hou, Yuxin ; Sun, Jun ; Li, Yinyan ; Li, Qiaobei ; Sun, Minglu ; Lou, Zhe ; Wang, Chunyan

In this study we evaluated the interaction of cinchonine (Cin) and immunoglobulin G (IgG). Then, Cin-IgG nanoparticles (NPs) were synthesized and characterized. Finally, the anticancer effects of free Cin and Cin-IgG NPs on MCF-7 breast cancer (BC) cells were evaluated. The results of spectroscopy measurements show that the IgG-Cin complex's quenching mechanism is static and the structure of IgG was partially changed following interaction with Cin. The prepared Cin-IgG NPs display a hydrodynamic size of 190 nm with a PDI of 0.269, a zeta potential of -38.05 mV, an EE% of 72.38 %, a LC% of 5.41 %, and a pH-sensitive drug release behavior. In the cellular assay, it was found that the calculated IC₅₀ concentrations of Cin, IgG NPs, and Cin-IgG NPs are 66.4 ± 5.39, >100, and 29.2 ± ± 4.11 μM, respectively, in MCF-7 BC cells. Finally, Cin-IgG NPs induce a greater effect on the overexpression of the Bax/Bcl-2 ratio and downregulation of PI3K/p-AKT compared to the free drug. In conclusion, this study shows that Cin has the potential to bind IgG as a human plasma protein, and its complexation into a NP form with IgG can boost its anti-BC effects.

2025-01-01·BIOCHEMICAL PHARMACOLOGY

Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss

Article

作者: Zou, Jian ; Deng, Wei ; Zhou, Yi ; Wang, Bin ; Zhang, Zhida ; Tang, Kai ; Wang, Zihe ; Chen, Junchun ; Zhao, Wenhua

Osteoporosis is characterized by excessive osteoclast activity leading to bone loss, decreased bone mineral density, and increased susceptibility to fractures. Through in vivo/vitro experiments, along with network pharmacology analysis, we aimed to explore the underlying mechanisms of Isoginkgetin (IGG) in inhibiting osteoclastogenesis, providing valuable insights for further research in the future. Firstly, we ascertained the safe concentration of IGG stimulation on BMMs, followed by a systematic exploration of the concentration gradient at which IGG inhibited osteoclastogenesis using TRAP analysis. An osteoporosis model was established to further validate the in vitro experimental findings by combining Micro-CT and immunohistochemical analysis. The results show that IGG did not exhibit cytotoxicity or proliferative effects on BMMs at concentrations equal to or less than 10 μM. Additionally, IGG inhibited the activity of osteoclastogenesis and bone resorption function at lower concentrations. RT-PCR and Western Blot results demonstrated that IGG could downregulate genes and proteins associated with osteoclastogenesis. The Western Blot results also showed that IGG inhibited the phosphorylation expression of P38, ERK, and P65 in the MAPK and NF-κB pathways. At the same time, it rescued the degradation of IκB-α at 15 and 60 min. IGG can also impact the relative expression levels of oxidative proteins such as SOD-1, HO-1, and catalase, thereby influencing cellular equilibrium and stress levels, ultimately inhibiting the formation of mature OC. In vivo experiments demonstrated that IGG alleviated bone loss caused by osteoclasts and improved relevant parameters of trabecular bone. So, IGG effectively attenuated osteoclastogenesis, and improved bone density, thereby portraying its role in osteoporosis management.

2024-11-01·JOURNAL OF CLINICAL IMMUNOLOGY

Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort

Article

作者: Bilgic Eltan, Sevgi ; Dikici, Ummugulsum ; Ozdemir, Oner ; Can, Salim ; Meric, Zeynep ; Aydogan, Metin ; Yalcin Gungoren, Ezgi ; Orhan, Fazil ; Karabiber, Esra ; Kiykim, Ayca ; Baris, Safa ; Karakoc-Aydiner, Elif ; Ozen, Ahmet ; Yorgun Altunbas, Melek ; Cokugras, Haluk ; Yakici, Nalan ; Eser Simsek, Isil

Abstract:

Background:

Immunoglobulin G replacement therapy (IgRT), intravenous (IV) and subcutaneous (SC) routes, is pivotal in treatment of primary immunodeficiencies (PID). In recent years, facilitated subcutaneous immunoglobulin (fSCIG), a combination of rHuPH20 and 10% IgG has emerged as a delivery method to combine advantages of both IV and SC.

Method:

In an observational prospective cohort, we investigated patient experience with fSCIG in PID patients from 5 PID centers for up to 12 months. We assessed the efficacy and safety of this treatment with patient/caregiver- and physician-reported indicators. Additionally, we analyzed patient treatment satisfaction (TSQM-9) and quality of life (QoL).

Results:

We enrolled 29 patients (22 pediatric and 7 adults; 14 females and 15 males; (median: 15, min–max: 2–40.9 years) who initiated fSCIG as IgRT-naive (n = 1), switched from conventional rapid-push 10% SCIG (n = 6) or IVIG (n = 22). Among the participants, 19 (65%) exhibited antibody deficiencies, 8 (27%) combined immunodeficiencies, and 2 (7%) immune dysregulations. Remarkably, targeted trough immunoglobulin G levels were achieved under all previous IgRTs as well as fSCIG. No severe systemic adverse drug reactions were documented, despite prevalent local (%86.45) and mild systemic (%26.45) adverse reactions were noted with fSCIG. Due to mild systemic symptoms, 2 patients switched from fSCIG to 10% SCIG. The patient satisfaction survey revealed a notable increase at 2-4th (p = 0.102); 5-8th (p = 0.006) and 9-12th (p < 0.001) months compared to the baseline. No significant trends were observed in QoL surveys.

Conclusion:

fSCIG demonstrates admissable tolerability and efficacy in managing PIDs in addition to notable increase of patients’ drug satisfaction with IgRT. The identified benefits support the continuation of this therapy despite the local reactions.

32

项与 Normal Human Immunoglobulin (CSL Behring) 相关的新闻（医药）

2024-12-24

·CSL Behring

2024年回顾｜邀您一同查看杰特贝林的年度徽章

告别2024 杰特贝林邀请您阅览 “年度荣耀徽章册” 重温这一年的荣耀时刻每一枚徽章象征着一个里程碑见证了杰特贝林员工对患者的不渝承诺诠释了杰特贝林的价值观—— 以患者为中心、创新、协作、诚信、卓越表现来看看我们的高光时刻！ 2025年崭新的篇章即将开启杰特贝林将坚守初心、矢志不渝致力于拯救更多患有罕见病和严重疾病的患者并不断提升他们的生活质量在健康事业的漫漫征途上锐意进取、突破创新、追求卓越将镌刻更多属于杰特贝林的荣耀印记！关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

基因疗法细胞疗法核酸药物

2024-11-14

·CSL Behring

他们的骑行，已经next level了！

中国约有2,000万罕见病患者，他们及其背后的2000万家庭都在承受着疾病带来的苦难。这些疾病虽然发病率低，但种类繁多、发病机制复杂，给患者及其家庭带来了巨大的挑战。他们面临的不仅是诊断的困难，还有治疗的艰辛、药物和治疗方案的稀缺以及沉重的经济负担。要克服这些挑战，需要医药企业、患者组织、医学机构和政府部门等相关方携手努力，共同建设可持续的罕见病诊疗生态体系。从全球到中国，杰特贝林始终积极联动社会各界力量，通过多元化行动，为罕见病患者带来希望。 Part.1/ CSL Behring 践行承诺，为爱出发 2024年9月至10月间，杰特贝林秉持“以患者为中心”的核心价值观，公益再出发，进行了涵盖多个地区和不同阶段的爱心骑行活动，为罕见病患者带来更多的关注和支持，并募集善款，以更好地推动罕见病事业的发展。 ~ 请点击查看视频 ~ 9月26日起，杰特贝林大中华区 7个办公室所在地区——上海、北京、广州、成都、武汉、中国台湾和中国香港的员工响应企业内部的公益号召，热情参与内部骑行活动，爱心凝聚，赋能罕见病患者。 ~ 请左右滑动，查看各地骑行照片 ~ 9月27日-10月6日，为全力支持蔻德罕见病中心（CORD）主办的“乐在骑中爱不罕见”公益骑行活动。杰特贝林大中华区商业运营副总裁兼总经理陈浩昌与多名员工在海南岛进行了为期10天、全程900多公里的的环岛骑行。环岛骑行的每一段路程，都体现出杰特贝林坚定不移的信念——用坚持和行动为罕见病患者带来切实的帮助和希望。 ~ 请左右滑动，查看各地骑行照片 ~ Part.2/ CSL Behring 以骑迹，绘就希望的轨迹公益骑行活动圆满落幕，杰特贝林共有120余位员工及家属参与其中，累积骑行近25,000公里，筹得善款超过50万元，分别赠予蔻德罕见病中心、台湾肌无力症关怀协会和香港HAE病友组织（HAE HK），以支持他们为罕见病患者提供的各项服务和活动。蔻德罕见病中心创始人兼主任黄如方表示： “杰特贝林与蔻德携手多年，始终致力于为罕见病患者群体提供坚定支持与服务。我们很高兴看到本次公益活动汇聚了社会各界爱心人士，共同投身于这场关爱行动之中。我们的愿景是为罕见病群体建立一个平等的、有尊严的、有希望的社会环境，让每个生命都能绽放光彩。” 台湾肌无力症关怀协会代表表示： “我们要特别感谢杰特贝林，联动肌无力症病友举办了这场公益骑行与捐款项目。肌无力症患者面临着社会认知不足、误诊率高、生活质量下降等挑战，通过这次活动，我们汇聚了更广泛的社会力量，进一步提升了公众对肌无力症这一罕见病症的认知和关注。” Part.3/ CSL Behring 心之所向，使命之光每一位骑友都是非凡的骑士，每一次骑行，都是对罕见病患者不屈不挠精神的崇高致敬；每一次出发，都是对自我极限的勇敢超越！此次公益骑行活动不仅是爱与希望的美好传递，同时也是杰特贝林大中华区使命的三大核心——Patient, People, Performance的生动体现：杰特贝林始终以患者为中心（Patient），深切关怀患者的需求与福祉；而员工（People）是杰特贝林最珍视的资产，我们帮助员工不断成长，激发员工的热情与活力，助力他们在医药行业实现个人价值，并为患者、为企业、为社会做出卓越表现（Performance），共同铸就一个更加美好的未来！道阻且长，步履不停终达彼岸；任重道远，持之以恒必有所成。陈浩昌杰特贝林大中华区商业运营副总裁兼总经理杰特贝林始终坚守对患者的初心，积极承担企业社会责任，持续通过提升罕见病认知、推广疾病教育、加速创新产品引入、提高药品的可及性等实际举措，全方位践行守护生命健康的使命。杰特贝林已连续两年开展公益骑行活动，希望能够唤起社会公众对罕见病患者的更多关注，联动全社会的力量，打破罕见病患者及其家庭的困境，共同创造一个充满希望和温暖的社会环境，助力他们早日重返正常生活，享受幸福人生。关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

高管变更

2024-09-20

·CSL Behring

为万分之一的罕见共创“骑迹”，杰特贝林公益骑行再出发

关于杰特贝林以拯救生命为己任的杰特贝林是全球生物治疗领域的先驱。我们致力于以创新的科技满足患者需求，开发并生产有助于治疗免疫缺陷、凝血障碍、心血管及代谢性疾病、呼吸疾病以及移植排斥的创新药物。我们使用血浆分馏、重组蛋白技术、细胞和基因治疗三大战略科学平台，支持持续创新，不断改进产品以实现未满足的医学需求和改善患者生活质量。杰特贝林拥有全球最大的血浆收集网络之一CSL Plasma。其母公司 CSL (ASX:CSL; USOTC:CSLLY) 的总部位于澳大利亚墨尔本，拥有32,000 名员工，为全球 100 多个国家提供拯救患者性命的医疗方式。自1986年，杰特贝林就开始为中国患者提供人血白蛋白，已成为中国市场该产品的主要供应商之一。现在杰特贝林透过全资子公司广州市君信药业有限公司在中国进行销售运营，并在中国五大城市 — 上海、北京、成都、广州和武汉均设有办公室。如想了解我们对生物技术的承诺相关的更多精彩故事，请访问网站 CSLBehring.com/Vita. 了解更多信息，请参考网站内容 www.cslbehring.com.cn. 请注意，本微信平台不是向CSL Behring报告不良事件的合适平台。如您有针对CSL Behring产品的不良事件报告，请通过邮箱 phv.china@cslbehring.com 联系我们，谢谢！点击阅读原文了解更多详情

基因疗法细胞疗法核酸药物

100 项与 Normal Human Immunoglobulin (CSL Behring) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
继发性免疫缺陷	欧盟	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	冰岛	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	列支敦士登	CSL Behring GmbH	2011-04-14
继发性免疫缺陷	挪威	CSL Behring GmbH	2011-04-14
获得性免疫缺陷综合征	欧盟	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	冰岛	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	列支敦士登	CSL Behring GmbH	2008-04-24
获得性免疫缺陷综合征	挪威	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	欧盟	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	冰岛	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	列支敦士登	CSL Behring GmbH	2008-04-24
丙种球蛋白缺乏血症	挪威	CSL Behring GmbH	2008-04-24
细菌感染	欧盟	CSL Behring GmbH	2008-04-24
细菌感染	冰岛	CSL Behring GmbH	2008-04-24
细菌感染	列支敦士登	CSL Behring GmbH	2008-04-24
细菌感染	挪威	CSL Behring GmbH	2008-04-24
慢性炎症性脱髓鞘性多发性神经病	美国	CSL Behring AG	2007-07-26
原发性免疫缺陷疾病	美国	CSL Behring AG	2000-07-27
免疫性血小板减少症	美国	CSL Behring AG	2000-07-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	美国	CSL Behring LLC	2024-08-28
新冠肺炎后遗症	临床3期	加拿大	CSL Behring LLC	2024-08-28
体位性心动过速综合征	临床3期	美国	CSL Behring LLC	2024-08-28
体位性心动过速综合征	临床3期	加拿大	CSL Behring LLC	2024-08-28
皮肌炎	临床3期	美国	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	日本	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	阿根廷	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	比利时	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	法国	CSL Behring LLC	2019-10-21
皮肌炎	临床3期	德国	CSL Behring LLC	2019-10-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02465359 (SCIG, CTgov)	N/A	慢性炎症性脱髓鞘性多发性神经病	15	Immune Globulin Subcutaneous (Human)	襯餘鬱齋窪憲獵襯願廠(壓積鏇獵窪鏇鹹窪壓積) = 夢糧襯構獵鹹壓積選餘網鬱淵夢獵窪簾繭網構 (範鹹齋窪鏇鏇願繭選鬱, 壓醖夢憲淵艱艱艱鹽艱 ~ 憲觸衊艱窪築築膚襯構) 更多	-	2024-10-08
NCT03919773 (iSTAND, CTgov)	临床1/2期	体位性心动过速综合征	30	IVIg (Treatment IVIG Arm)	遞憲夢憲繭鏇願衊壓憲(範簾淵齋齋襯夢築艱鑰) = 簾蓋醖網鹹鹹蓋醖網糧壓鹽繭廠觸淵鹽窪淵鑰 (鑰蓋廠鹽艱齋選夢糧構, 構壓製襯顧襯繭艱醖衊 ~ 鹹鏇積艱膚選夢簾齋遞) 更多	-	2024-09-19
NCT03919773 (iSTAND, CTgov)	临床1/2期	体位性心动过速综合征	30	albumin (Treatment Albumin Arm)	遞憲夢憲繭鏇願衊壓憲(範簾淵齋齋襯夢築艱鑰) = 壓製襯艱醖獵蓋餘憲願壓鹽繭廠觸淵鹽窪淵鑰 (鑰蓋廠鹽艱齋選夢糧構, 築襯鹹遞蓋獵鹽淵餘壓 ~ 遞憲鬱願憲廠膚製夢襯) 更多	-	2024-09-19
AAAAI2024	N/A	原发性免疫缺陷疾病	-	Immune Globulin Subcutaneous 16.5%	遞艱鑰築衊網顧餘襯艱(網網廠簾鏇艱醖蓋鏇膚) = 餘蓋觸範齋顧網獵蓋構憲築願構鬱衊鹽膚窪夢 (製範願觸製築製憲襯廠 ) 更多	积极	2024-02-23
AAAAI2023	N/A	原发性免疫缺陷疾病	57	IGSC 16.5%	廠鹽膚遞範鏇獵膚艱鏇(衊範鏇製窪鏇繭淵遞願) = 44 bacterial RTIs were reported in 29 patients (rate of 0.77 infections/patient/year), with 1 serious 鑰鏇繭廠襯膚鏇構範簾 (鹹遞廠艱廠壓糧蓋艱顧 )	-	2023-02-01
EHA2021	N/A	慢性淋巴细胞白血病	10	Subcutaneous Immunoglobulins	積鹹積選齋淵夢夢構膚(鑰鏇夢顧壓夢淵積糧蓋) = 構範製餘獵艱襯廠積網憲繭艱淵壓艱顧鏇遞鹹 (鹹憲獵遞窪鏇糧壓構襯 )	-	2021-06-09
NCT04044690 (Pubmed \| Rheumatology (Oxford)) 人工标引	临床3期	肌炎一线	20	Privigen	鬱製壓築鑰膚製鹹淵範(餘窪窪繭鹹蓋淵衊繭憲) = 鹽醖選獵願憲襯願憲廠遞糧壓獵顧衊願繭鹽壓 (餘廠鹹積鹽蓋憲鏇獵憲 ) 更多	积极	2021-04-06
NCT03593902 (CAST, CTgov)	临床2/3期	系统性硬皮病	9	Autologous Stem Cells+Mesna+Methylprednisolone+Fludarabine+CYCLOPHOSPHAMIDE+rATG+G-CSF+IVIg+Rituximab	艱淵淵獵鑰鏇鏇顧鏇衊(遞觸鑰鬱顧積壓餘衊網) = 構窪積窪衊齋襯願願選餘壓壓鑰範構鑰鑰糧鑰 (觸獵鑰築衊獵遞餘積憲, 鏇製獵鏇鬱製積鹹製製 ~ 鑰顧壓膚築襯鹹顧積鏇) 更多	-	2020-08-12
NCT03033745 (HILO Study, AAAAI2020)	临床4期	原发性免疫缺陷疾病	16	Manual IgPro20 push infusions at high flow rate	鹽襯壓構蓋繭獵壓壓夢(鏇積蓋壓鹹衊鏇遞築艱) = 鑰壓網蓋鑰遞廠衊簾齋憲衊艱觸衊鏇膚衊築餘 (鹹糧淵醖顧顧製鏇鹽夢 )	-	2020-02-01
AAAAI2020	N/A	原发性免疫缺陷疾病	33	IGSC 16.5%	夢顧獵齋鏇選蓋艱蓋築(選觸艱衊壓淵製鏇願願) = A total of 22/33 (67%) patients reported local-site reactions (rate 0.60/infusion), with injection pain and swelling most common. Systemic reactions were reported in 20/33 (61%) of patients (0.47/infusion), with headache and fatigue most common. Incidence of reactions was highest with the first infusion. Therapy was discontinued in one per patient request 夢獵範壓鏇築鹹遞糧鹹 (醖選獵鹹繭構積簾廠鹽 ) 更多	-	2020-02-01